Clinical Pipeline

---

Shattuck’s lead partnered compound entered the clinic in April 2019, and its lead wholly-owned compound will enter the clinic in the second half of 2020.

To date, Shattuck’s Agonist Redirected Checkpoint (ARC) platform has yielded more than 300 bi-functional fusion protein drug candidates, two of which are currently in clinical trials for the treatment of life-threatening and debilitating diseases. The three lead ARC molecules are designed to block checkpoint molecules that limit the immune system (PD-1, CD47, and CSF1R) while simultaneously stimulating T-cell receptors to initiate an immune response (OX40 or CD40). Shattuck’s lead partnered asset, SL-279252 (PD1-Fc-OX40L), has advanced to the clinic in less than two years and is currently enrolling patients at five sites across the United States, Canada, and Europe. Shattuck’s internal lead asset, SL-172154 (SIRPα-Fc-CD40L), will be enrolling patients in its clinical trials during the second half of 2020.

Program	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Status
SL-279252 PD1-Fc-OX40L						Enrolling Phase 1 / Data Expected Late 2021
SL-172154 - I.V. SIRPα-Fc-CD40L						Phase 1 Study Open
SL-172154 - I.T.I. SIRPα-Fc-CD40L						Phase 1 Study Open
SL-115154 CSF1R-Fc-CD40L						Expected IND Second Half 2021

Drug	Indication	Stage
SL-279252	PD1-Fc-OX40L	Phase 1
SL-172154 - I.V.	SIRPα-Fc-CD40L	Preclinical
SL-172154 - I.T.I.	SIRPα-Fc-CD40L	Preclinical
SL-115154	CSF1R-Fc-CD40L	Preclinical

---

Discovery and Preclinical Pipeline

---

With over 300 bi-functional fusion protein compounds created to date, Shattuck has a robust pipeline of therapeutic candidates for the treatment of cancer and autoimmune disease.